D. E. Shaw & Co., Inc. Uni Qure N.V. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
3 transactions
Others Institutions Holding QURE
# of Institutions
148Shares Held
34.2MCall Options Held
1.07MPut Options Held
603K-
Vestal Point Capital, LP New York, NY4.73MShares$36.6 Million2.03% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.09MShares$23.9 Million1.03% of portfolio
-
683 Capital Management, LLC New York, NY1.98MShares$15.3 Million0.88% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$14.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.52MShares$11.8 Million0.0% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $362M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...